Deprilept en es it fr

Deprilept Brand names, Deprilept Analogs

Deprilept Brand Names Mixture

  • No information avaliable

Deprilept Chemical_Formula

C20H23N

Deprilept RX_link

No information avaliable

Deprilept fda sheet

Deprilept msds (material safety sheet)

Deprilept MSDS

Deprilept Synthesis Reference

M. Wilhelm, et al. Helv. Chim. Acta. 52, 1385 (1969)

Deprilept Molecular Weight

277.403 g/mol

Deprilept Melting Point

93 oC

Deprilept H2O Solubility

Slightly soluble

Deprilept State

Solid

Deprilept LogP

5.546

Deprilept Dosage Forms

Tablet (10, 25, 50, and 75mg film coated)

Deprilept Indication

For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.

Deprilept Pharmacology

Maprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline re-uptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.

Deprilept Absorption

Completely absorbed following oral administration

Deprilept side effects and Toxicity

LD50=~900 mg/kg (Orally in rats); LD50=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.

Deprilept Patient Information

No information avaliable

Deprilept Organisms Affected

Humans and other mammals